A Phase 1b, Open-Label, Single-Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of ANX1502 in Participants with Primary Cold Agglutinin Disease

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507017-10-00

Acronym

ANX1502-CAD-02

Enrollment

Registered

2023-11-13

Start date

2024-06-17

Completion date

2025-12-05

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Cold Agglutinin Disease (CAD)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Austria

None listed

Source: EU CTIS · Data processed: Feb 4, 2026